Key Highlights

● Second-quarter revenue rose 39% to about $3.0 million.

● Gross margin reached about 20.9%, against a gross loss a year earlier.

● The net loss narrowed 16% to about $5.7 million.

● A one-for-fifty reverse stock split took effect on July 31, 2026.

Picard Medical, Inc. (NYSE American:PMI) is drawing attention because its latest quarterly report, released on August 19, 2026, showed faster revenue growth and a narrower quarterly loss, while the company also manages a listing compliance plan and a need for fresh funding. The shares trade on NYSE American under the ticker PMI, and the group operates in the medical device sector.

Business and sector

Picard Medical is a holding company whose operations run through its subsidiary SynCardia Systems, LLC, based in Tucson, Arizona. SynCardia makes the SynCardia Total Artificial Heart, an implantable system for patients with end-stage heart failure. According to the company, the device is approved by the US Food and Drug Administration and by Health Canada, and it is the only commercially available total artificial heart in the United States and Canada.

The company reports more than 2,100 implants across hospitals in 27 countries. It is also developing a next-generation device called Emperor, which it believes could support a first-of-its-kind fully implantable design. Emperor remains in preclinical development, so it is not yet approved or available for patients.

Latest verified results

On August 19, 2026 Picard Medical reported results for the three months ended June 30, 2026. Revenue was approximately $3.0 million, up 39% from approximately $2.1 million a year earlier, with the company attributing the increase to about $0.8 million of higher sales in the United States.

Gross profit was approximately $0.6 million, compared with a gross loss of approximately $0.1 million in the prior-year quarter, lifting gross margin to about 20.9%. The net loss narrowed by 16% to approximately $5.7 million from approximately $6.7 million.

For the first half of 2026, revenue rose 50% to approximately $4.1 million. Higher US sales were partly offset by lower European sales. The half-year net loss increased to approximately $13.3 million from approximately $12.3 million, as higher research and development and administrative costs outweighed lower other expenses.

Financials and context

The results show a business improving its unit economics while still spending heavily on development. A move from a gross loss to a gross margin of roughly 21% is meaningful, yet the company remains far from profitability, with a quarterly net loss almost twice its quarterly revenue.

Corporate events add context. In July 2026 NYSE American accepted the company's compliance plan, and stockholders approved a reverse stock split, which took effect on July 31, 2026 at a ratio of one for fifty. A reverse split raises the quoted share price mechanically and does not change the underlying value of a holding.

The company has said it is evaluating additional financing. A Form 8-K dated October 6, 2026 reported that three investors received 3% convertible notes with warrants, which can dilute existing shareholders if converted or exercised.

Key risks

The most prominent risk is liquidity. The quarterly report filed on August 19, 2026 flagged low cash and going-concern risk, meaning there is doubt about the ability to keep operating without additional funding.

Listing risk is second. The company says it is working to regain compliance with NYSE American standards within the time its accepted plan allows, and failure could lead to delisting, which would typically reduce liquidity. Emperor needs extensive further development before any approval.

Liquidity Is the Test for the Next Quarter

Picard Medical heads into its next reporting period with improving unit economics and heavy spending: second-quarter revenue of about $3.0 million, a gross margin of about 20.9% and a net loss of about $5.7 million, almost twice quarterly revenue, with the first-half net loss rising to about $13.3 million. Corporate events add pressure, as NYSE American accepted its compliance plan in July 2026, a one-for-fifty reverse stock split took effect on July 31, and three investors received 3% convertible notes with warrants in a Form 8-K dated October 6, 2026.

The next quarterly filing should show cash, progress on the compliance plan, the terms of any new financing, and whether US sales growth continues to offset weaker European demand. Emperor remains in preclinical development, which leaves the SynCardia Total Artificial Heart as the company's commercial product.